申请人:Novo Nordisk A/S
公开号:US20140073564A1
公开(公告)日:2014-03-13
Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
新型酰化
胰岛素类似物表现出对
蛋白酶的抵抗力,可以有效地通过肺部或口服给药。
胰岛素类似物包含B25H和
A14E或
A14H。